Cellivate Technologies is a Bio-tech startup that raised $1 million in its ongoing seed funding round led  by Antler. The funding round had the participation of the firm’s new and existing investors including  Venture Catalysts, We Founder Circle, and Hatcher+. The startup plans to use these fresh proceeds to  fuel its business growth, scale its operations, enhance its research & development, and expand in the  market. This marks the second round of investment for the company since its inception. 

The startup develops nanotechnology to study issues related to growing cells. The company provides  innovative solutions to address challenges faced in bio-manufacturing and cell culture areas. The  company also offers several flagship products including a serum based on novel cells to replace fetal  bovine serum and advanced microcarriers for accelerating cell growth. The firm provides a product  called ProCYTE, designed to improve adhesion and growth in cells. Cellivate Technologies claims to  offer advanced micro-carriers and cell-based serum alternatives that reduce costs while addressing  challenges in the cell culture process and improving efficiency. The startup aims to provide affordable  and advanced solutions to improve biotechnology. The company previously secured $1 million during  its seed funding round in 2023.  

The company believes that the advancement in cell culture and biomanufacturing technologies will  reduce the need for animal slaughtering since the products derived from animals can be generated  through cells. The main focus of the startup is to use this investment to produce more innovative  products and expand its operations. The Biotech startup provides cell-based serums and technologies  to tackle the ethical challenges in cell culture. The firm aims to revolutionize healthcare and cell-related  biotechnologies across the world and offer the best solutions. The investment shows the trust of  investors in the startup’s market potential. 

Cellivate Technologies plans to use some of its investment to expand its biotech research and advance  cell-related technologies. The startup faces competition from other biotech companies including  Nano3D Bioscience, Ribon Therapeutics, and Gristone Bio. Cellivate and its three competitors have  raised a total fund of $4.55 million across three funding rounds from four investors. The development  came just after the biotech startup saw increased interest from investors globally. The market research  showed that the cell culture market is expected to grow and reach 33 billion USD in the next six years.  

Conclusion: 

Cellivate Technologies is a Singapore-based biotech startup that secured $1 million in its seed funding  round. The funding round was led by Anthler with the participation of the firm’s new and existing  investors including Hatcher+, Venture Catalysts, and We Founder Circle. The company intends to use  this fresh capital to accelerate its product development, scale its operations, enhance its platform, and  expand in the market. The company is working on creating innovative solutions to address the  challenges in biomanufacturing and cell culture. The company also offers a flagship product called  ProCYTE to enhance microcarriers and scale up cell growth. This marks the second funding round for  the startup following its $1 million seed funding round in 2023.